News Search Results
Sep 30, 2026, 16:23 ET Huntington Bancshares Incorporated Announces Third Quarter 2026 Earnings Call Details
webcast in the Investor Relations section of Huntington's website or through a dial-in telephone number at (877) 407-8029 or (201) 689-8029; conference ID # 13762987.A replay of the webcast will be archived in the Investor Relations section of Huntington's website. A telephone replay will be available
More news about: Huntington Bancshares Incorporated
Sep 30, 2026, 10:00 ET Huntington Bank Announces Investments in United Housing, Boys & Girls Clubs of Greater Memphis to Support Families and Future Growth
are involved with United Housing through program sponsorships, volunteering, board service and first-time homebuyer education and seminars.Huntington's commitment to affordable housing is a core pillar in its broader community development strategy. Across its markets, the bank makes investments
More news about: Huntington Bancshares Incorporated
Sep 30, 2026, 08:30 ET Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference
endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust
More news about: Neurocrine Biosciences, Inc.
Sep 29, 2026, 20:12 ET uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)
uniQure's four-year AMT-130 Huntington's disease benefit came in smaller than its three-year result, and QURE shares plummeted. SueWallSt notifies investors of a pending investigation into potential securities law violations.NEW YORK, Sept.
More news about: SueWallSt.com
Sep 28, 2026, 16:05 ET Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer
endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust
More news about: Neurocrine Biosciences, Inc.
Sep 28, 2026, 12:00 ET Huntington Bank to Add Signage, Expand Presence at Regional Headquarters in Charlotte
the heart of Charlotte's financial district. Huntington's signage will face South Tryon Street, giving the bank's name a prominent position on the city's skyline. Installation of the signage is expected in the coming weeks. "We applaud Huntington's continued growth and investment in uptown Charlotte,"
More news about: Huntington Bank
Sep 21, 2026, 16:30 ET PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
expectations with respect to PTC's license and collaboration agreement with Novartis Pharmaceuticals Corporation for votoplam for the treatment of Huntington's disease including its right to receive development, regulatory and sales milestones, profit sharing and royalty payments from Novartis, the design
More news about: PTC Therapeutics, Inc.
Sep 17, 2026, 10:03 ET Skyhawk Therapeutics 公佈 SKY-0515 治療亨廷頓病的第 1/2 期臨床試驗 15 個月最終結果
1.59 分，這正是本領域在探索潛在有效藥物的早期研究中所期待看到的訊號。功能、運動及認知指標所呈現的持續改善趨勢，仍須在正在進行的安慰劑對照研究中進一步驗證，但對 HD 治療及本研發項目而言，這都是令人振奮的進展。」Beth Israel Deaconess Medical Center 的 Huntington's Disease Society of America 卓越中心主任 Samuel Frank 博士表示。「SKY-0515 同時降低 mHTT 及 PMS1 水平，針對的是亨廷頓病的兩種核心致病機制。如果這些發現能在正在開展的第 2/3 期 FALCON-HD 關鍵性臨床研究項目中得到證實，可能會對全球
More news about: Skyhawk Therapeutics
Sep 17, 2026, 08:07 ET Skyhawk Therapeutics annonce les résultats finaux à quinze mois de l'essai clinique de phase 1/2 du SKY-0515 chez des patients atteints de la maladie de Huntington
mais il s'agit d'une avancée prometteuse pour la MH et pour le programme », a déclaré le Dr Samuel Frank, directeur du centre d'excellence de la Huntington's Disease Society of America au Beth Israel Deaconess Medical Center. « La double réduction de mHTT et de PMS1 induite par SKY-0515 s'attaque à deux
More news about: Skyhawk Therapeutics
Sep 17, 2026, 06:01 ET Canary Speech Awarded on TIME's List of the World's Top HealthTech Companies 2026 List
neurological conditions, including depression, anxiety, mild cognitive impairment, Alzheimer's disease, multiple sclerosis, Parkinson's disease, and Huntington's disease. Canary Safety™ provides real-time detection of aggression and violence risk, while Canary Wellness™ helps organizations monitor workforce
More news about: Canary Speech
Sep 16, 2026, 16:37 ET Skyhawk Therapeutics gibt die endgültigen Ergebnisse nach 15 Monaten aus der klinischen Phase-1/2-Studie mit SKY-0515 bei Patienten mit Huntington-Krankheit bekannt
externen Kontrollgruppe für den natürlichen Krankheitsverlauf eine Differenz von +1,59 Punkten bei der Veränderung des Wertes auf der Composite Unified Huntington's Disease Rating Scale (cUHDRS) gegenüber dem Ausgangswert auf.Die Unterschiede zugunsten von SKY-0515 waren bei allen vier cUHDRS-Komponenten
More news about: Skyhawk Therapeutics
Sep 16, 2026, 06:27 ET Skyhawk Therapeutics anuncia los resultados finales de 15 meses del ensayo clínico de fase 1/2 de SKY-0515
constituyen un avance prometedor para la enfermedad de Huntington y para el programa", afirmó el Dr. Samuel Frank, director del Centro de Excelencia de la Huntington's Disease Society of America en el Beth Israel Deaconess Medical Center. "La doble reducción de mHTT y PMS1 que logra SKY-0515 aborda dos mecanismos
More news about: Skyhawk Therapeutics
Sep 15, 2026, 12:46 ET Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease Patients
program," said Dr. Samuel Frank, Director of the Huntington's Disease Society of America Center of Excellence at Beth Israel Deaconess Medical Center. "SKY-0515's dual reduction of mHTT and PMS1 addresses two core pathogenic mechanisms of Huntington's disease. If these findings are confirmed in the ongoing
More news about: Skyhawk Therapeutics
Sep 15, 2026, 12:20 ET Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease Patients
program," said Dr. Samuel Frank, Director of the Huntington's Disease Society of America Center of Excellence at Beth Israel Deaconess Medical Center. "SKY-0515's dual reduction of mHTT and PMS1 addresses two core pathogenic mechanisms of Huntington's disease. If these findings are confirmed in the ongoing
More news about: Skyhawk Therapeutics
Sep 14, 2026, 09:40 ET Huntington Bank to Relocate Historic Downtown Columbus Branch to New Storefront at Broad and High
Move will maintain Huntington's longtime presence on Capitol Square and create a modern, accessible customer experienceCOLUMBUS, Ohio, Sept. 14, 2026 /PRNewswire/ -- Huntington Bank today announced
More news about: Huntington Bank
Sep 09, 2026, 16:05 ET Huntington Bancshares Incorporated to Present at the 2026 Barclays Global Financial Conference
Webcast InformationInterested investors may access the live audio webcast in the investor relations section of Huntington's website (
More news about: Huntington Bancshares Incorporated
Sep 08, 2026, 09:00 ET Huntington Names Brant Standridge President
growth and performance of the bank."The appointment builds on Standridge's work establishing and leading Huntington's Growth Council, which brings together leaders from across Huntington's revenue-producing businesses to identify and capitalize on long-term growth opportunities. Standridge has also
More news about: Huntington Bancshares Incorporated
Sep 02, 2026, 16:01 ET Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids,* as well
More news about: Neurocrine Biosciences, Inc.
Sep 02, 2026, 09:00 ET Huntington Bank Names Ameesh Vakharia Chief Marketing and Digital Products Officer
In this newly created role, Ameesh will lead Huntington's integrated marketing and digital products organization, bringing together brand, marketing and digital product management to strengthen the Huntington
More news about: Huntington Bank
Aug 31, 2026, 09:30 ET Huntington Bank Opens First Branch in Mount Pleasant
Opening expands Huntington's South Carolina branch network to five full-service locationsMOUNT PLEASANT, S.C., Aug. 31, 2026 /PRNewswire/ -- The Huntington National Bank (Huntington) today announced
More news about: Huntington Bank
Aug 25, 2026, 09:22 ET Afecta Pharmaceuticals Granted New US Patent for Neuro-Immuno Modulators
compounds have applicability for treatment of complex degenerative disorders of the brain such asParkinson's diseaseHuntington's diseaseAlzheimer's diseaseThe discovery of this family of neuro-immuno modulators was achieved using Afecta's proprietary
More news about: Afecta Pharmaceuticals
Aug 18, 2026, 08:45 ET Huntington Bank Launches National Business for Community Associations and Management Partners
multi-association structures."Our new business is designed to help these groups operate with confidence, control and clarity," said Sabine Liedel, Huntington's senior managing director of its national deposits business, which oversees association banking. "It's powered by a dedicated client-care team featuring
More news about: Huntington Bancshares Incorporated
Aug 14, 2026, 07:00 ET Huntington Bank Hires Laricke Blanchard as Director of Congressional and Regulatory Relations
growth.""Having a dedicated team in D.C. marks a big milestone in Huntington's 160-year history and will position us to better represent the interests of our customers, communities, colleagues and investors," said Barbara Benham, Huntington's chief public affairs officer. "Laricke is deeply committed to
More news about: Huntington Bancshares Incorporated
Aug 12, 2026, 16:01 ET PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
expectations with respect to PTC's license and collaboration agreement with Novartis Pharmaceuticals Corporation for votoplam for the treatment of Huntington's disease including its right to receive development, regulatory and sales milestones, profit sharing and royalty payments from Novartis, the design
More news about: PTC Therapeutics, Inc.
Aug 12, 2026, 08:30 ET Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia
controlled (tardive dyskinesia). involuntary movements (chorea) of Huntington's disease. INGREZZA or INGREZZA SPRINKLE do not cure the cause of involuntary movements, and do not treat other symptoms of Huntington's disease, such as problems with thinking or emotions. It is not known
More news about: Neurocrine Biosciences, Inc.